MTN 025 (HOPE)

Status:Completed
Phase:Open Label, III
Principal Investigator(s):John Steytler
Objective:MTN-025 or the HIV Open-label Prevention Extension (HOPE) study is a follow-on trial to assess the continued safety of and adherence to a vaginal ring containing dapivirine in women. Results summary: High uptake and persistent use in this open-label extension study support DVR as an HIV-1 prevention option for women. Last updated October 20, 2022
Prevention Option(s):Microbicides
Study Design:Open label
Arms and Assigned Interventions
DescriptionFollowing demonstration of safety and efficacy of the dapivirine vaginal ring in MTN-020, eligible MTN-020 participants will be offered enrollment into MTN-025, a trial designed to obtain additional safety and adherence data in women.
Mode of DeliveryRing
ARMsExperimental
Results: HIGH UPTAKE AND REDUCED HIV-1 INCIDENCE IN AN OPEN-LABEL TRIAL OF THE DAPIVIRINE RING
Official Code: NCT02858037
Related Publications:
Safety, uptake, and use of a dapivirine vaginal ring for HIV-1 prevention in African women (HOPE): an open-label, extension study
Sharing Objective Measures of Adherence to a Vaginal Microbicide Promotes Candor About Actual Use and Bolsters Motivation to Prevent HIV
Trial Sponsors: DAIDS, NICHD, NIH, NIMH
Start Date
End Date
July 18, 2016
October 10, 2018
Enrollment:1,576
Age range: 18 Years ↔ 40 Years
Population:Cisgender Women